//www.igerbera.com/journals/jamadermatology en - us Wed, 26 Apr 2023 00:00:00 GMT Wed, 26 Apr 2023 11:43:37 GMT Silverchair jamams@jamanetwork.org support@www.igerbera.com //www.igerbera.com/journals/jamadermatology/fullarticle/2804251 Wed, 26 Apr 2023 00:00:00 GMT Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with few effective treatments and only a single therapy approved by the US Food and Drug Administration (FDA). The clinical heterogeneity of HS has hindered development of accurate, reproducible, responsive, and clinically meaningful outcome measures, which has been one of the key challenges to HS therapeutic development. Efforts to harmonize morphological and surgical procedural definitions have been foundational in establishing a common lexicon to support outcome measure development and therapeutic advancement. Accurate measures of disease response are not only critical for clinical trials but are also fundamental for future studies comparing agents across trials and examining therapeutic performance in real-world evidence studies. To date, more than 16 different physician-reported instruments and outcome measures, many of which lack validation data to confirm that results were clinically relevant and reliable, have been used to measure disease activity in HS clinical trials. In this issue of JAMA Dermatology, Garg and Hidradenitis Suppurativa Core Outcomes Set International Collaboration (HiSTORIC) colleagues seek to validate and describe the psychometric properties of the novel HS Investigator Global Assessment (HS-IGA) using data from the Union Chimique Belge (UCB) phase 2 study evaluating bimekizumab for HS. 10.1001/jamadermatol.2023.0784 2804251 //www.igerbera.com/journals/jamadermatology/fullarticle/2804250 Wed, 26 Apr 2023 00:00:00 GMT 10.1001/jamadermatol.2023.0771 2804250 //www.igerbera.com/journals/jamadermatology/fullarticle/2804249 Wed, 26 Apr 2023 00:00:00 GMT This case report describes a 46-year-old woman presented with numerous monomorphic, mildly erythematous, and skin-colored smooth indurated papules that coalesced into plaques that involved the upper and lower eyelids, forehead, medial cheeks, cutaneous lips, and chin. 10.1001/jamadermatol.2023.0528 2804249 //www.igerbera.com/journals/jamadermatology/fullarticle/2804248 Wed, 26 Apr 2023 00:00:00 GMT This secondary analysis of data from a phase 2 randomized clinical trial assesses the psychometric properties of the Hidradenitis Suppurativa Investigator Global Assessment score. 10.1001/jamadermatol.2023.0797 2804248 //www.igerbera.com/journals/jamadermatology/fullarticle/2804247 Wed, 26 Apr 2023 00:00:00 GMT This scoping review examines current approaches to qualitative dermatologic research and the publication trends of these studies. 10.1001/jamadermatol.2023.0839 2804247 //www.igerbera.com/journals/jamadermatology/fullarticle/2804017 Wed, 19 Apr 2023 00:00:00 GMT 这个队列研究调查natomic location of keratinocyte carcinomas in the US using a large claims data set. 10.1001/jamadermatol.2023.0611 2804017 //www.igerbera.com/journals/jamadermatology/fullarticle/2804016 Wed, 19 Apr 2023 00:00:00 GMT This case report describes symmetrically distributed red to violaceous fine telangiectasias in a lacelike pattern on the dorsal feet and ankles. 10.1001/jamadermatol.2022.6229 2804016 //www.igerbera.com/journals/jamadermatology/fullarticle/2804015 Wed, 19 Apr 2023 00:00:00 GMT This case report describes a 52-year-old woman who presented with asymptomatic telangiectasia on her lower limbs. 10.1001/jamadermatol.2023.0757 2804015 //www.igerbera.com/journals/jamadermatology/fullarticle/2804014 Wed, 19 Apr 2023 00:00:00 GMT This randomized clinical trial evaluates the efficacy and safety of interleukin-13–targeted treatment with tralokinumab monotherapy in adolescents with atopic dermatitis. 10.1001/jamadermatol.2023.0627 2804014

map